Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia

Rasim Gucalp, Paul Ritch, Peter H. Wiernik, P. Ravi Sarma, Alan Keller, Stephen P Richman, Kurt Tauer, James Neidhart, Lawrence E. Mallette, Robert Siegel, Christine J. VandePol

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.

Original languageEnglish
Pages (from-to)134-142
Number of pages9
JournalJournal of Clinical Oncology
Volume10
Issue number1
StatePublished - Dec 1 1992
Externally publishedYes

Fingerprint

pamidronate
Etidronic Acid
Second Primary Neoplasms
Hypercalcemia
Safety
Calcium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gucalp, R., Ritch, P., Wiernik, P. H., Ravi Sarma, P., Keller, A., Richman, S. P., ... VandePol, C. J. (1992). Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Journal of Clinical Oncology, 10(1), 134-142.

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. / Gucalp, Rasim; Ritch, Paul; Wiernik, Peter H.; Ravi Sarma, P.; Keller, Alan; Richman, Stephen P; Tauer, Kurt; Neidhart, James; Mallette, Lawrence E.; Siegel, Robert; VandePol, Christine J.

In: Journal of Clinical Oncology, Vol. 10, No. 1, 01.12.1992, p. 134-142.

Research output: Contribution to journalArticle

Gucalp, R, Ritch, P, Wiernik, PH, Ravi Sarma, P, Keller, A, Richman, SP, Tauer, K, Neidhart, J, Mallette, LE, Siegel, R & VandePol, CJ 1992, 'Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia', Journal of Clinical Oncology, vol. 10, no. 1, pp. 134-142.
Gucalp, Rasim ; Ritch, Paul ; Wiernik, Peter H. ; Ravi Sarma, P. ; Keller, Alan ; Richman, Stephen P ; Tauer, Kurt ; Neidhart, James ; Mallette, Lawrence E. ; Siegel, Robert ; VandePol, Christine J. / Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. In: Journal of Clinical Oncology. 1992 ; Vol. 10, No. 1. pp. 134-142.
@article{e74afa473cd947e7bb54d9c1cc63cb76,
title = "Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia",
abstract = "Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70{\%} (21 of 30) of patients, whereas EHDP did so in 41{\%} (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78{\%} v 67{\%}). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.",
author = "Rasim Gucalp and Paul Ritch and Wiernik, {Peter H.} and {Ravi Sarma}, P. and Alan Keller and Richman, {Stephen P} and Kurt Tauer and James Neidhart and Mallette, {Lawrence E.} and Robert Siegel and VandePol, {Christine J.}",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "10",
pages = "134--142",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia

AU - Gucalp, Rasim

AU - Ritch, Paul

AU - Wiernik, Peter H.

AU - Ravi Sarma, P.

AU - Keller, Alan

AU - Richman, Stephen P

AU - Tauer, Kurt

AU - Neidhart, James

AU - Mallette, Lawrence E.

AU - Siegel, Robert

AU - VandePol, Christine J.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.

AB - Purpose: This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of Cancer-related hypercalcemie. Patients and Methods: Sixty-five male and female adult patients with Cancer and corrected calcium levels of ≥ 12.0 mg/dL after 24 hours of hydration were randomized to receive either 60 mg APD given as a single 24-hour infusion or 7.5 mg/kg EHDP given as a 2-hour infusion daily for 3 days. Results: APD normalized corrected calcium levels in 70% (21 of 30) of patients, whereas EHDP did so in 41% (14 of 34) of patients (P = .026). The mean corrected serum calcium level decreased from 14.6 to 10.5 mg/dL in the APD-treerted group and from 13.8 to 11.6 mg/dL in the EHDP-treated group within the first week of treatment. There was no difference in response to APD in patients without versus those with bone metastases (78% v 67%). Both drugs were well tolerated. Conclusion: This study demonstrated that a single 60-mg infusion of APD is safe and more effective than EHDP given at the dose of 7.5 mg/kg for 3 days in the treatment of Cancer-related hypercalcemia.

UR - http://www.scopus.com/inward/record.url?scp=0026593561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593561&partnerID=8YFLogxK

M3 - Article

C2 - 1727915

AN - SCOPUS:0026593561

VL - 10

SP - 134

EP - 142

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -